Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9016269 | 1.00 | TSHR (0.44) | TSHRKMT2AMEN1HTR1AIDH1 | |
| SCHEMBL13184074 | 1.00 | TSHR (0.44) | TSHRKMT2AMEN1HTR1AIDH1 | |
| SCHEMBL5287000 | 1.00 | TSHR (0.44) | TSHRKMT2AMEN1HTR1AIDH1 | |
| SCHEMBL5298515 | 1.00 | TSHR (0.44) | TSHRKMT2AMEN1HTR1AIDH1 | |
| SCHEMBL15744030 | 0.84 | FADS1 (0.53) | KMT2AMEN1FADS1PTGDR2 | |
| SCHEMBL15743940 | 0.84 | MDM2 (0.39) | TSHRIDH1FADS1 | |
| SCHEMBL20794196 | 0.84 | FADS1 (0.53) | KMT2AMEN1FADS1PTGDR2 | |
| SCHEMBL15744028 | 0.84 | FADS1 (0.53) | KMT2AMEN1FADS1PTGDR2 | |
| SCHEMBL15744019 | 0.81 | MEN1 (0.44) | KMT2AMEN1MAOA | |
| SCHEMBL15743933 | 0.81 | MDM2 (0.50) | TSHRFADS1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2020-07-16 | — | — | US | disclosed |
| US-20170204065-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-07-20 | — | — | US | disclosed |
| CN-106822206-A | It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-06-13 | — | — | CN | disclosed |
| CN-106729031-A | A kind of pharmaceutical composition for treating cold in children | 济南昊雨青田医药技术有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-05-18 | — | — | US | disclosed |
| CN-106668096-A | Pharmaceutical composition for preventing and treating hyperostosis | 济南昊雨青田医药技术有限公司 | 2017-05-17 | — | — | CN | disclosed |
| US-9643927-B1 | Process for the preparation of kinase inhibitors and intermediates thereof | AERIE PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2387555-B1 | METHOD FOR MAKING PHENYLETHYLAMINE COMPOUNDS | JOHNSON MATTHEY PLC (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2540698-A1 | Method for making phenylethylamine compounds | Johnson Matthey PLC (GB) | 2013-01-02 | — | — | EP | disclosed |
| EP-2387555-A1 | METHOD FOR MAKING PHENYLETHYLAMINE COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2011-11-23 | — | — | EP | disclosed |
| WO-2010058206-A1 | METHOD FOR MAKING PHENYLETHYLAMINE COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2010-05-27 | — | — | WO | disclosed |
| US-20100125146-A1 | METHOD FOR MAKING PHARMACEUTICAL COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2010-05-20 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | TSHR 2302/4885KMT2A 2365/4885MEN1 4409/4885 |
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | TSHR 2488/4885KMT2A 2006/4885MEN1 1216/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | TSHR 3807/4885KMT2A 2879/4885MEN1 4126/4885 |
| US-20170204065-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | TSHR 2488/4885KMT2A 2006/4885MEN1 1216/4885 |
| US-20100125146-A1 | METHOD FOR MAKING PHARMACEUTICAL COMPOUNDS | ADORA2B, ADORA1, ADRA2B | TSHR 20/4885KMT2A 1478/4885MEN1 1335/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | TSHR 4292/4885KMT2A 4422/4885MEN1 2853/4885 |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | TSHR 3773/4885KMT2A 3596/4885MEN1 2750/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | TSHR 3773/4885KMT2A 3596/4885MEN1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.